You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Parnell Pharmaceuticals delisting from Nasdaq
Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility
#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability
Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles
Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018
Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.
The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.
The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.